What genetic mutations are commonly found in Prostate Cancer

Common Genetic Mutations in Prostate Cancer

I'll walk you through the genetic mutations that doctors look for in prostate cancer, organized by how they're typically used in treatment decisions.

DNA Repair Gene Mutations (Most Clinically Important)

According to the NCCN Guidelines, these are the mutations that most directly impact your treatment options:

BRCA1 and BRCA2 Mutations

These are "tumor suppressor" genes—think of them as your cells' quality control system. When they're mutated, your cells can't repair DNA damage properly, allowing cancer to develop and progress.

Why this matters: If you have a BRCA1 or BRCA2 mutation, you're often a good candidate for PARP inhibitors (drugs like olaparib). These medications work by blocking your cells' ability to repair DNA, which is especially effective when BRCA genes are already broken. Research shows BRCA2 mutations respond particularly well to PARP inhibitors.

ATM Mutations

The ATM gene is another "cancer protection" gene that helps prevent prostate cancer by fixing DNA damage. When mutated, this protection is lost.

Clinical significance: ATM mutations can also respond to PARP inhibitor therapy, though typically not as robustly as BRCA mutations.

Other DNA Repair Genes

According to NCCN Guidelines for metastatic prostate cancer, doctors also test for mutations in:

• PALB2
• RAD51D
• CHEK2
• CDK12
• FANCA

These genes all play roles in fixing DNA damage, and mutations in them may indicate responsiveness to targeted therapies.

---

Mismatch Repair Gene Mutations (Lynch Syndrome Genes)

These genes correct errors that happen when DNA copies itself:

• MLH1
• MSH2
• MSH6
• PMS2

What they mean: When these genes are mutated, errors accumulate in your DNA, creating what's called Microsatellite Instability (MSI-High). According to cancer immunotherapy experts, approximately 3-5% of prostate cancers are MSI-High.

Treatment implications: If you have MSI-High prostate cancer, you may be eligible for Keytruda (pembrolizumab), an immunotherapy drug that helps your immune system recognize and attack cancer cells. The FDA has approved Keytruda specifically for MSI-High cancers.

Important note: If mismatch repair defects are found, you should be referred for genetic counseling to assess whether you have Lynch syndrome, which increases risk for other cancers (colorectal, uterine, and others).

---

Germline vs. Somatic Mutations: What's the Difference?

According to NCCN Guidelines, there are two types of genetic mutations to understand:

Germline mutations = inherited mutations you're born with (in every cell)

• Can be passed to children
• Affect cancer risk for other family members
• Require genetic counseling

Somatic mutations = acquired mutations that develop only in cancer cells

• Not inherited
• Specific to your tumor
• Help guide treatment decisions

---

Who Should Get Genetic Testing?

According to NCCN Guidelines, germline testing is recommended if you have:

• Metastatic, regional (node-positive), very-high-risk, or high-risk localized prostate cancer (regardless of family history)
• Family history of prostate, breast, ovarian, or colorectal cancer
• Family history of known mutations (BRCA1, BRCA2, ATM, CHEK2, etc.)
• Ashkenazi Jewish ancestry
• Any other type of cancer diagnosis

For somatic tumor testing (testing the cancer cells themselves), NCCN Guidelines recommend:

• Multigene testing for DNA repair gene alterations in patients with metastatic prostate cancer
• Testing can be considered in patients with regional prostate cancer
• Testing for MSI-H or mismatch repair deficiency in metastatic castration-resistant prostate cancer

---

How Testing is Done

According to NCCN Guidelines, tumor testing can use:

• Tissue biopsy from the prostate or metastatic lesions (preferred)
• Liquid biopsy (blood test for circulating tumor DNA) when tissue biopsy isn't safe or feasible
• Next-generation sequencing (NGS) to identify mutations

---

Important Reality Check

As noted in expert webinars on prostate cancer treatment, genetic testing identifies actionable mutations in only about 20% of patients. This means 80% of the time, no specific mutation is found that directly guides treatment. However, this doesn't mean testing isn't valuable—it helps your doctor understand your cancer's biology and explore all available options.

---

Questions to Ask Your Oncologist

1. Should I have germline (inherited) genetic testing? (Especially important if you have family history of cancer)
2. Should my tumor be tested for somatic mutations? (Particularly if you have metastatic or high-risk disease)
3. If mutations are found, what treatment options does this open up for me?
4. Should I be referred to a genetic counselor to discuss results and implications for my family?
5. Can I have liquid biopsy (blood test) instead of tissue biopsy if tissue sampling isn't feasible?

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.